Immunostimulatory Motifs Enhance Antiviral siRNAs Targeting Highly Pathogenic Avian Influenza H5N1 by Stewart, Cameron R. et al.
Immunostimulatory Motifs Enhance Antiviral siRNAs
Targeting Highly Pathogenic Avian Influenza H5N1
Cameron R. Stewart*, Adam J. Karpala, Sue Lowther, John W. Lowenthal, Andrew G. Bean
Infection and Immunity, The Commonwealth Scientific and Industrial Research Organisation Australian Animal Health Laboratory, Geelong, Victoria, Australia
Abstract
Highly pathogenic avian influenza (HPAI) H5N1 virus is endemic in many regions around the world and remains a significant
pandemic threat. To date H5N1 has claimed almost 300 human lives worldwide, with a mortality rate of 60% and has caused
the death or culling of hundreds of millions of poultry since its initial outbreak in 1997. We have designed multi-functional
RNA interference (RNAi)-based therapeutics targeting H5N1 that degrade viral mRNA via the RNAi pathway while at the
same time augmenting the host antiviral response by inducing host type I interferon (IFN) production. Moreover, we have
identified two factors critical for maximising the immunostimulatory properties of short interfering (si)RNAs in chicken cells
(i) mode of synthesis and (ii) nucleoside sequence to augment the response to virus. The 5-bp nucleoside sequence 59-
UGUGU-39 is a key determinant in inducing high levels of expression of IFN -a,- b,- l and interleukin 1- b in chicken cells.
Positioning of this 59-UGUGU-39 motif at the 59- end of the sense strand of siRNAs, but not the 39- end, resulted in a rapid
and enhanced induction of type I IFN. An anti-H5N1 avian influenza siRNA directed against the PB1 gene (PB1-2257) tagged
with 59-UGUGU-39 induced type I IFN earlier and to a greater extent compared to a non-tagged PB1-2257. Tested against
H5N1 in vitro, the tagged PB1-2257 was more effective than non-tagged PB1-2257. These data demonstrate the ability of an
immunostimulatory motif to improve the performance of an RNAi-based antiviral, a finding that may influence the design of
future RNAi-based anti-influenza therapeutics.
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Introduction
Since the first reports of virus transmission from poultry to
humans in 1997, highly pathogenic avian influenza (HPAI) H5N1
virus has spread throughout much of Asia, Europe, the Middle
East and Africa [1]. Cases of H5N1 in domestic poultry and water
birds have been reported in over 40 countries since 2003, with the
death or preventative culling of more than 200 million chickens
causing devastation amongst poultry industries [2], particularly in
South-East Asia. During 2004, widespread outbreaks of H5N1
occurred throughout Asia, where the virus crossed the species
barrier to infect humans [3]. Since then there have been almost
500 confirmed human cases of H5N1 infection reported in 12
countries [4]. Furthermore, the 60% human mortality rate of
H5N1 is alarming when compared to the approximate 2%
mortality rate of seasonal influenza A [5]. H5N1 remains a
significant threat of becoming a pandemic human disease, a
scenario tied closely to global outbreaks in poultry. Therefore,
novel therapies to combat zoonotic viruses like H5N1 are urgently
needed. While vaccines against H5N1 are available, the lack of
strain-specific vaccines during early-stage outbreaks creates a
demand for alternative therapies. Compounding this is the
shortcomings of existing antivirals and their loss of utility due to
the emerging viral resistance to classes of neuraminidase (NA) and
M2 ion channel inhibitors [6].
RNA interference (RNAi), the natural cellular pathway in which
dsRNA input sequence is used to degrade target mRNA, is the
basis for many therapeutics currently being developed against
major human diseases (reviewed in [7,8]). The exquisite specificity
of RNAi-mediated gene silencing, coupled with a potential to
silence virtually any gene, makes RNAi an attractive basis for
therapeutic design. Current clinical trials of RNAi-based thera-
peutics include treatments against several viral diseases, such as
respiratory syncytial virus and hepatitis B [9]. However it is well-
established that select RNAi molecules can trigger off-target pro-
inflammatory and antiviral cytokines which in many cases cause
unwanted side effects [10]. This phenomenon, known as immunos
timulatory RNAi (isRNAi), may derive from the evolution of
RNAi as an antiviral defence mechanism, as observed in plants
[11] and Drosophila [12]. Double-stranded RNA may activate the
type I interferon (IFN) pathway as an immune mechanism
directed to impact on viral replication. Downstream outcomes of
type I IFN production and binding to its receptor include the
shutdown of RNA and protein synthesis in virally-infected cells,
apoptosis of virally-infected cells and the induction of IFN-
stimulated genes (ISGs) that coordinate downstream antiviral
measures [13]. Stimulation of innate immune responses by RNAi
molecules would therefore appear to not be a random process, and
several studies have identified factors that confer immunostimu-
latory properties to RNA, including nucleoside sequence [14,15,
16], short hairpin RNA (shRNA) promoters [17,18] and
polymerases used to synthesise short interfering RNAs (siRNAs)
[16,19,20]. Whilst so called off-target effects of RNAi are
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greatly from multiple response pathways directed towards
prevention of viral replication.
In this study we have explored the application of isRNAi in
chickens with the aim of developing isRNAi antivirals that
combats H5N1 by silencing viral genes whilst simultaneously
triggering antiviral host immune responses to eradicate the virus.
We identify a nucleoside motif that strongly induces type I IFN in
chicken cells, and explore the strategy of attaching this motif to
siRNAs designed against H5N1. By combining a silencing RNA
with a nucleoside immuno-enhancers, we have created a new
RNAi molecule that complement and synergise in a double-action
antiviral.
Results
siRNAs designed against three different conserved regions of the
influenza A genome were selected based on their silencing ability
(PA-2087 and PB2-2240 [21], M-592 – T. Doran, unpublished
data) (Table 1, sequences 1–3). To test the ability of these siRNAs
to induce cytokine production in chicken cells, these three siRNAs
were synthesized using T7 RNA polymerase and transfected into
the immortalized chicken fibroblast cell line, DF-1. Since DF-1
cells have previously been shown to produce high levels of IFN- b
in response to the dsRNA mimetic polyI:C [22], they provide a
model cell line for assessing the type I IFN response to siRNA. M-
592, PA-2087 and PB2-2240 induced IFN-b to differing levels,
effectively giving low, moderate and high induction of IFN-b,
respectively, relative to induction by polyI:C, with maximum levels
observed after 24 h (Figure 1).
The ability of distinct sequences to modulate the immunosti-
mulatory properties of siRNAs in mammalian cells was illustrated
recently [15] where the induction of pro-inflammatory cytokines
was directly related the presence of a 5 bp motif, 59-UGUGU-39.
We conducted a bioinformatics search of RNAi sequences
targeting influenza A and found that PB1-2257, a 19 bp siRNA
targeting the PB1 segment of influenza A contains a motif from
base pairs 3–7, 59-UCUGU-39, remarkably similar to 59-UGUGU-
39 (Table 1, sequence 4). Previous studies have shown PB1-2257 to
be an effective silencer of influenza A subtype H1N1 replication
[21]. We created a modified version of PB1-2257 (immunostimu-
latory (is)PB1-2257) where a single substitution at position 4 (C to
G) was made, hence creating a 59-UGUGU-39 motif (Table 1,
sequence 5). An irrelevant siRNA (Scramble) was also synthesized
as a negative control by random shuffling of the PB1-2257
sequence (Table 1, sequence 6). isPB1-2257 induced IFN-a, IFN-
b, IFN-l and IL-1b mRNA to a greater extent than PB1-2257 and
Scramble after transfection into DF-1 cells (Figure 2). Interestingly,
PB1-2257, isPB1-2257 and Scramble induced IL-1b, but not the
related cytokine, IL-18.
It has been reported that mode of synthesis can impact the
immunostimulatory properties of siRNAs [10]. To test this
parameter in our study, chemically-synthesized siRNAs (c-siRNAs)
and siRNAs synthesized using T7 RNA polymerase (T7-siRNAs)
were transfected into DF-1 cells at identical concentrations and the
Table 1. siRNAs used in this study
Sequence # siRNA Sequence
1 M-592 59-CUACAGCUAAGGCUAUGGA-39
39-GAUGUCGAUUCCGAUACCU-59
2 PA-2087 59-GCAAUUGAGGAGUGCCUGA-39
39-CGUUAACUCCUCACGGACU-59
3 PB2-2240 59-CGGGACUCUAGCAUACUUA-39
39-GCCCUGAGAUCGUAUGAAU-59
4 PB1-2257 59-GAUCUGUUCCACCAUUGAA-39
39-CUAGACAAGGUGGUAACUU-59
5 isPB1-2257 59-GAUGUGUUCCACCAUUGAA-39
39-CUACACAAGGUGGUAACUU-59
6 Scramble 59-AAGAGAGCGAGAUCUACAC-39
39-UUCUCUCGCUCUAGAUGUG-59
7 2Me-isPB1-
2257
59-GAU[mG]UGUUCCACCAUUGAA-39
39-CUACACAAGGUGGUAACUU-59
8 uPB1-2257 59-UGUGUGAUCUGUUCCACCAUUGAA-39
39-ACACACUAGACAAGGUGGUAACUU-59
9 PB1-2257u 59-GAUCUGUUCCACCAUUGAAUGUGU-39
39-CUAGACAAGGUGGUAACUUACACA-59
doi:10.1371/journal.pone.0021552.t001
Figure 2. Increased immunostimulatory properties of siRNAs
containing 59-UGUGU-39 in chicken cells. mRNA levels of cytokines
in DF-1 cells induced by PB1-2257, isPB1-2257 and Scramble (20 pmol)
after 8 h. Each value is the mean + standard deviation (3 replicates) and
representative of data from 3 experiments a=p,0.001 between isPB1-
2257 and both PB1-2257 and Scramble after 8 h.
doi:10.1371/journal.pone.0021552.g002
Figure 1. Induction of IFN-b in chicken DF-1 cells by siRNAs. IFN-
b mRNA levels induced in DF-1 cells by siRNAs (20 pmol) or polyI:C
(0.8 mg). Each value is the mean + standard deviation (3 replicates) and
representative of data from 3 experiments. a=p,0.001 between M-592
and PA-2087 after 8 h. b=p,0.001 between PA-2087 and PB2-2240
after 8 h.
doi:10.1371/journal.pone.0021552.g001
Bi-Functional siRNAs Inhibit H5N1
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post-transfection (Figure 3 A), the T7-isPB1-2257 had induced a
large increase in IFN- b. However, this increase was not observed
for the c-siRNA variant, nor either form of PB1-2257 or Scramble.
At 24 h (Figure 3 B), induction of IFN- b was 10-fold higher for c-
isPB1-2257 compared to T7-isPB1-2257. Scramble induced
moderate IFN-b expression at 24 h as a T7-siRNA, but not as a
c-siRNA. These results demonstrate that for both T7-siRNAs and
c-siRNAs, there is a sequence-dependent induction of IFN-b. This
induction is more rapid with the additional input of T7 synthesis.
To further probe the role of 59-UGUGU-39 in IFN stimulation, a
chemically-synthesized derivative of isPB1-2257 was synthesized
with a methyl group masking the 59-UGUGU-39 motif (Table 1,
sequence 7). Masking of the 59-UGUGU-39 motif caused an almost
total abolition of IFN-b induction by isPB1-2257 at 24 h
(Figure 3C). To test the role of 59 phosphate groups present on
siRNAs synthesised by T7 RNA polymerase on immunostimula-
tion, T7-isPB1-2257 and T7-PB1-2257 were treated with shrimp
alkaline phosphatase (SAP) to remove 59 phosphate groups and
transfected into DF-1 cells. Compared to untreated controls, levels
of IFN-b induced by isPB1-2257 and PB1-2257 were reduced by
approximately 40% by phosphatase treatment (Figure 3D). These
results confirm the importance of both the 59-UGUGU-39 motif
and mode of siRNA synthesis on immunostimulation.
We next investigated the receptor responsible for inducing type
I IFN in response to immunostimulatory siRNAs in chicken cells.
Immunostimulatory siRNAs act via Toll-like receptor 7 (TLR7) in
mammals [14]. However, QRT-PCR demonstrated that DF-1
cells express almost non-detectable levels of TLR7 (not shown),
suggesting that other dsRNA-sensing molecules, such as other
TLRs or RIG-like helicases, may recognise PB1-2257. siRNAs
were transfected into DF-1 cells to create cell populations knocked
down for melanoma-differentiation-associated gene 5 (Mda5) and
TLR3. siRNAs to silence chicken TLR3 and chicken Mda5 have
been described previously and reduce gene expression levels by
.75% [22,23]. QRT-PCR results confirmed that siRNAs and did
not themselves induce significant increases in type I IFN (data not
shown). A strong induction of IFN-b in control DF-1 cells was
observed 24 h after stimulation with PB1-2257 (Figure 4). This
response was reduced by 90% in TLR3 knock down DF-1 cells
(p,0.001). In contrast, cells with reduced levels of Mda5 did not
show a significant reduction in IFN-b expression.
Figure 3. Immunostimulatory properties of T7-siRNAs and c-siRNAs in chicken cells. IFN-b mRNA levels were measured in DF-1 cells
transfected with T7-siRNAs (white bars, 20 pmol) or c-siRNAs (black bars, 20 pmol) at (A) 8 h or (B) 24 h. a=p,0.05 between paired white bars (T7-
siRNA) and black bars (c-siRNA). (C) IFN-b mRNA levels in DF-1 cells induced by isPB1-2557 (chemically synthesized, 20 pmol) or 2Me-isPB1-2257
(chemically-synthesized, 20 pmol). a.=p,0.001 between isPB1-2257 and 2Me-isPB1-2257 at 24 h. (D) IFN-b mRNA levels in DF-1 cells transfected with
T7-siRNAs (20 pmol) untreated (white bars) or treated with shrimp alkaline phosphatase (SAP) (black bars). Data shows IFN-b mRNA levels 8 h post-
transfection. a.=p,0.05 between levels of IFN-b in cells transfected with untreated siRNAs or SAP-treated siRNAs. Results are representative of 3
separate experiments.
doi:10.1371/journal.pone.0021552.g003
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more immunostimulatory than PB1-2257, this effect was achieved
by altering the PB1-2257 sequence, which is critical for silencing.
To create a multi-functional antiviral with both immunostimula-
tory and silencing properties, we attached 59-UGUGU-39 to either
the 59 or the 39 ends of c-PB1-2257 without disrupting the
silencing sequence itself (Table 1, sequence 8 and 9). This
modification resulted in a 3-fold enhancement of the immunos-
timulatory profile for the PB1-2257 variant tagged with the 59-
UGUGU-39 motif at the 59 end (uPB1-2257) relative to the un-
tagged molecule (Figure 5). In contrast, tagging at the 39 end (PB1-
2257u) appeared to have little enhancing effect.
We tested siRNA-mediated inhibition of influenza A/Vietnam/
1203/2004 (H5N1) in vitro. Since DF-1 cells are poor at supporting
H5N1 virus replication (data not shown), the immortalised chicken
macrophage cell line, HD-11, was used for this experiment. Firstly,
we investigated whether 59-UGUGU-39-tagged PB1-2257 showed
enhanced immunostimulatory properties in HD-11 cells
(Figure 6A). Similar to results observed for DF-1 cells, HD-11
cells transfected with uPB1-2257 showed increased levels of IFN-b
at 8 h compared to cells transfected with PB1-2257 or PB1-2257u.
When infected with H5N1 virus (Figure 6B), HD-11 cells
transfected with uPB1-2257 showed significantly reduced levels
of virus compared to cells transfected with PB1-2257 or PB1-
2257u. To ensure that siRNA-mediated inhibition of H5N1 virus
growth was not due to toxicity, the viability of HD-11 cells
transfected with siRNAs was measured using Alamar Blue. At the
time of H5N1 infection (24 h post-transfection), cells transfected
with siRNAs showed viability levels comparable to untreated cells,
(Figure 6C) suggesting that antiviral properties of siRNAs are not
related to compromised cell viability.
Discussion
Highly pathogenic avian influenza (HPAI) H5N1 virus remains
a significant pandemic threat. The development of novel antivirals
to assist in protection against H5N1 virus will present healthcare
industries with a new approach in dealing with an outbreak of viral
infection. This study is the first to demonstrate the effective
inhibition of highly pathogenic avian influenza by directed
immunostimulatory siRNAs. Furthermore, we have identified
several factors critical to the immunostimulatory properties of
siRNAs in chicken cells. Firstly, the importance of sequence was
demonstrated by comparing the immunostimulatory properties of
PB1-2257 and isPB1-2257 in DF-1 cells, where a single nucleoside
substitution had a large impact on the kinetics and extent of IFN
production. In addition, we showed that siRNAs synthesized
enzymatically had different immunostimulatory properties to
chemically-synthesized sequence-matched variants, demonstrating
how the mode of siRNA synthesis influences immunostimulation
in the chicken. This difference in immunostimulation between
siRNA variants was caused partially by cellular recognition of 59-
triphosphate groups present in T7-siRNAs. Interestingly, a recent
report suggested that DF-1 cells do not produce type I IFN in
response to 59-triphosphate siRNAs due to an absence of retinoic
acid-inducible gene I protein (RIG-I) in chickens, and that a
decreased type I IFN response in chickens in response to viral
RNA epitopes may explain the increased susceptibility of chickens
to H5N1 virus [24]. However, our findings would suggest that DF-
1 cells can produce type I IFN in response to phosphorylated
siRNAs and that this process is critically sequence-dependent.
This study provides further evidence that the immunostimula-
tory properties of siRNAs, for several years considered an
unwanted side effect of siRNA research, can be utilised to improve
the performance of antiviral siRNAs. This synergistic effect was
recently achieved in a mammalian system by introducing a
microRNA-like non-pairing uridine-bulge into siRNA passenger
strands, resulting in immunostimulatory siRNAs that enhanced
protection of human immune cells from Semliki Forest virus [25].
We have harnessed the immunostimulatory properties of the 59-
UGUGU-39 motif, and illustrated how the differential positioning
of the 59-UGUGU-39 motif at the 59 end of PB1-2257 can have a
major impact on immunostimulation and subsequent antiviral
protection. In chicken cells infected with H5N1, the effect of 59
tagging lead to a 2-log enhancement of anti-viral activity.
Interestingly, a 21 bp siRNA duplex consisting entirely of poly-
UG has recently been shown to induce type I IFNs in chicken
splenocytes more effectively than siRNAs lacking poly-UG repeats
[26]. This result further demonstrates the immunostimulatory
Figure 4. T7-PB1-2257 requires TLR3 but not Mda5 for type I
IFN induction in DF-1 cells. Control (white bars), Mda5-knockdown
(striped bars) and TLR3-knockdown (black bars) DF-1 cells were
transfected with PB1-2257 (T7-siRNA, 20 pmol). mRNA levels of IFN-b
were measured by QRT-PCR 24 h after PB1-2257 stimulation.
a=p,0.001 between IFN-b levels induced by PB1-2257 in control cells
(white bars) and TLR3 KD cells (black bars). Results are representative of
3 separate experiments.
doi:10.1371/journal.pone.0021552.g004
Figure 5. Attaching 59-UGUGU-39 to PB1-2257 increases induc-
tion of type I IFN. mRNA RNA levels of IFN-b in DF-1 cells transfected
with chemically-synthesized PB1-2257, PB1-2257 tagged with 59-
UGUGU-39 at the 59 end (uPB1-2257) or at the 39 end (PB1-2257u) (all
20 pmol) for 8 h or 24 h. a=p,0.05 between levels of IFN-b induced by
uPB1-2257 and PB1-2257. Each value is the mean + standard deviation
(3 replicates) and representative of data from 3 experiments.
doi:10.1371/journal.pone.0021552.g005
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UGUGU-39 and supports our strategy to enhance PB1-2257 using
this motif.
A major finding from this study is that immunostimulation of
chicken cells by T7-siRNAs involves TLR3, a result that is perhaps
surprising given that immune recognition of short dsRNA has
been assigned to TLR7 and TLR8 in other species [27]. However,
it is well established that TLR3, while long-associated with the
recognition of long (.46 bp) dsRNA, can be activated by RNA
duplexes as short as 21 bp [28,29]. An example of this activation is
the design of siRNAs against vascular endothelial growth factor-A
as a treatment for age-related macular degeneration [30]. It was
subsequently demonstrated that numerous dsRNAs inhibited
angiogenesis in a sequence-independent manner by activating
TLR3 and the downstream production of IFN-c and IL-12 [29].
Our results suggest a hitherto unreported role for chicken TLR3 in
the recognition of short dsRNA. This is of particular interest given
that the apparent lack of RIG-I in the chicken genome would
suggest other receptors are responsible for viral dsRNA surveil-
lance. Having already established the role for chicken TLR3 in the
recognition of long dsRNA [22], our results suggest that TLR3
plays a dual role in recognition of both long and short dsRNA.
It has recently been shown that RNAi potency and efficacy can
be improved by creating siRNAs as longer, 27 b.p. Dicer
substrates [31,32]. One possible explanation for the enhanced
anti-viral impact of UGUGU-tagged PB1-2257 is that lengthening
the siRNA creates a Dicer substrate with improved potency.
However, two factors would suggest that the improved anti-viral
properties of UGUGU-tagged PB1-2257 are caused by immuno-
stimulation. Firstly, we created two longer variants of PB1-2257;
uPB1-2257 and PB1-2257u. Only for uPB1-2257 did we observe
increased IFN production and improved anti-viral properties,
suggesting this result was not caused by non-specific lengthening of
the siRNA duplex. Secondly, the addition of UGUGU to PB1-
2257 created a 24 b.p. duplex – which in theory should be too
short to act as a Dicer substrate.
The ability of 59-UGUGU-39 to incite antiviral immune responses
in different species [15], coupled with the use of siRNAs targeting
viral genes rather than host genes, raises the prospect of
immunostimulatory siRNAs being developed as therapeutics
against a diverse range of viruses across different species. This
point is particularly relevant given the ability of several devastating
viruses, including swine-origin influenza virus and H5N1, to
transmit across species. In addition, the combinational use of
siRNAs designed against conserved regions of viral genomes would
create therapeutics effective against various virus subtypes. For
example, therapeutic siRNAs targeting conserved regions of the
influenza A genome would silence H5N1 and H1N1, that have
caused recent devastation of poultry and pork industries respective-
ly,andcausedhumanfatalities.Asthe availabilityofa strain-specific
vaccine is unlikely in the early stages of a virus outbreak, and given
the rapid onset of mortality, immunostimulatory siRNAs represent
an alternative therapy to combat viral infections.
Materials and Methods
siRNAs
siRNAs were synthesized by T7 RNA polymerase using the
Ambion SilencerH siRNA Construction Kit according to manu-
facturer’s instructions (Ambion inc, Austin, Texas) with template
oligonucleotides purchased from Geneworks (Adelaide, Australia).
Chemically-synthesized siRNAs were purchased from Sigma (St
Louis, MO). siRNAs used to reduce chicken TLR3 [22] and Mda5
[23]) have been described previously.
Figure 6. Inhibition of H5N1 influenza virus growth by 59-
UGUGU-39-tagged PB1-2257. (A) IFN-b mRNA levels in HD-11 cells
transfected with c-siRNAs (all 20 pmol). Data shows IFN-b mRNA levels
8 h post-transfection. a.=p,0.01 between levels of IFN-b in cells
transfected with uPB1-2257 versus PB1-2257. (B) TCID50 of H5N1 virus
growth in HD-11 cells transfected with c-siRNAs (5 pmol, 96 well plate)
or polyI:C (0.1 mg). Cells were transfected with siRNAs and infected with
H5N1 virus 24 h later at dilutions of virus of 10
-1to 10
27. Cells were
rinsed with fresh medium before the addition of virus. TCID50 values
were measured 72 h post-infection. Each value is the mean + standard
deviation (4 replicates). a=p,0.05 between virus levels in cell
supernatants of cells treated with PB1-2257 or uPB1-2257. (C) Viability
of HD-11 cells 24 h post-transfection with c-siRNAs (5 pmol, 96 well
plate) as measured by Alamar blue. Results are representative of 3
separate experiments.
doi:10.1371/journal.pone.0021552.g006
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The continuous chicken fibroblast cell line DF-1 (American
Type Culture Collection (ATCC), CRL-12203) were maintained
in DMEM supplemented with 10% (v/v) heat-inactivated foetal
calf serum (FCS), 2 mM L-glutamine, 1.5% (w/v) sodium
bicarbonate, 100 U/mL penicillin and 100 mg/mL streptomycin.
The continuous chicken macrophage cell line HD-11 was
maintained in RPMI medium supplemented with 10% (v/v)
FCS, 10 mM HEPES, 2 mM L-glutamine, 100 U/mL penicillin,
and 100 mg/mL streptomycin. African green monkey kidney
epithelial Vero cells (ATCC CRL-81) were maintained in DMEM
supplemented with 10% (v/v) FCS, 100 U/mL penicillin and
100 mg/mL streptomycin. All cells were incubated at 37uC under
a5 %C O 2/95% air atmosphere.
Transfections
For RNA extraction, DF-1 and HD-11 cells were cultured in
12-well plates (1610
5 cells per well) for 24 h before transfection in
medium lacking penicillin and streptomycin. Cells were transfect-
ed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according
to manufacturer’s guidelines. After 4 h, the transfection medium
was changed to growth medium containing penicillin (100 U/mL)
and streptomycin (100 mg/mL) and 10% FCS. For viral infections,
HD-11 cells were seeded in 96 well plates (6610
3 cells per well) for
24 h before transfection in medium lacking penicillin and
streptomycin. Cells were transfected using Lipofectamine 2000
according to manufacturer’s guidelines. After 4 h, the transfection
medium was changed to growth medium containing penicillin
(100 U/mL) and streptomycin (100 mg/mL) and 10% FCS.
RNA isolation, reverse transcription and quantitative
real-time PCR
RNA was harvested using Tri-reagent (Sigma) according to
manufacturer’s instructions. One microgram of extracted RNA
was treated with DNase (Sigma) according to manufacturer’s
instructions and reverse-transcribed to complementary DNA
(cDNA) using a Reverse Transcription kit (Promega, Madison
WI). Quantitative real-time PCR (QRT-PCR) experiments were
conducted to measure cytokine expression levels. All quantification
data was normalised against chicken GAPDH. QRT-PCR was
performed on an ABI Prism 7700 Sequence Detection System
(Applied Biosystems). The comparative threshold cycle (Ct)
method was used to derive fold change gene expression. Primers
and probes were designed using Primer Express software (Applied
Biosystems). Where possible, the probe sets were designed across
intron:exon boundaries. PCR cycling was performed as follows:
95uC for 1 min, followed by 40 cycles of 95uC for 15 sec, 61uC for
30 sec and 68uC for 30 sec.
Quantitative real-time PCR probes. Probes for the
detection of chicken IFN-a, IFN-b, IFN-l and GAPDH have
been described previously [22,33]. Sequences for detecting
chicken IL-1b and chicken IL-18 are shown in Table 2.
Treatment of siRNAs with shrimp alkaline phosphatase
siRNAs synthesized using T7 RNA polymerase were treated
with shrimp alkaline phosphatase (SAP) according to manufactur-
ers guidelines (Promega). Briefly, siRNAs were treated with SAP
(1u SAP/mg siRNA) at 37uC for 30 min. Samples were heated to
65uC for 10 min to inactivate SAP.
Viruses
Influenza A/Vietnam/1203/2004 (H5N1) was passaged in the
allantoic fluid of 10-day embryonated specific pathogen-free
chicken eggs. H5N1 virus was handled in BSL3 conditions at
the CSIRO Australian Animal Health Laboratory (AAHL).
Allantoic fluid was harvested, aliquoted and stored at 280uC for
inoculations. Virus titer was measured by plaque assays, whereby
serial 10-fold dilutions of viruses were incubated on Vero cells for
30 minutes and then cells were overlayed with medium containing
1% agar. Two days after infection, plaques were visualized by
staining with crystal violet.
TCID50
10-fold dilutions of H5N1 virus were made in PBS and added to
a 96-well tissue culture plate containing Vero cells in growth
medium. Plates were incubated for 5 days at 37uC, 5% CO2 and
scored for cytopathic effect. The infectious titer was calculated by
the method of Hawkes [34].
Cell viability assay
Viability of HD-11 cells was measured using Alamar Blue
(Invitrogen) according to manufacturer’s guidelines. Briefly, HD-
11 cells seeded in 96-well tissue culture plates were incubated with
10 mL Alamar Blue for 4 h at 37uC5 %C O 2. Sample absorbance
was measured at 540 nm and 620 nm using a Biotek EL808
absorbance microplate reader (Biotek, Winooski, VT). Cell
viability was calculated by subtracting the 620 nm absorbance
values of the cell culture medium alone from 540 nm absorbance
values of experimental wells.
Statistics
The difference between two groups was statistically analysed by
Student’s t-test. A p-value of ,0.05 was considered significant.
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